Organic compounds -- part of the class 532-570 series – Organic compounds – Unsubstituted hydrocarbyl chain between the ring and the -c-...
Reexamination Certificate
1997-12-08
2002-07-02
Shah, Mukund J. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Unsubstituted hydrocarbyl chain between the ring and the -c-...
Reexamination Certificate
active
06414142
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to an improved process for preparing potassium clavulanate, a novel crystalline form of potassium clavulanate and the use thereof in treating bacterial infections.
BACKGROUND OF THE INVENTION
Clavulanic acid and its salts are disclosed in British Patent No. 1508977 as &bgr;-lactamase inhibitors capable of enhancing the antibacterial effectiveness of &bgr;-lactam antibiotics such as penicillins and cephalosporins against many &bgr;-lactamase producing bacteria. Antibacterial compositions comprising potassium clavulanate and amoxycillin are commercially available under the trade name ‘Augmentin’ (registered Trademark of SmithKline Beecham Corporation), and certain oral dry unit-dose antibacterial compositions of potassium clavulanate and amoxycillin are described in British Patent No. 2005538. Antibacterial compositions comprising potassium clavulanate and ticarcillin are commercially available under the trade name ‘Timentin’ (registered Trademark of SmithKline Beecham Corporation). Potassium clavulanate may also be formulated with other penicillins and cephalosporins to enhance their antibacterial efficacy, and also may be formulated alone for separate co-administration with penicillins and cephalosporins.
British Patent No. 1508977 also discloses that salts of clavulanic acid can be obtained by absorbing the clavulanate anion in filtered broth onto an anion exchange resin, eluting therefrom with an electrolyte, desalting the resulting solution, applying the desalted solution to a further anion exchange resin, chromatographically eluting therefrom with an electrolyte, desalting the resulting solution and thereafter removing the solvent. This process can be used to give acceptable yields of pure material, but the use of resin columns involves significant investment and they can introduce limitations in large scale production operations.
British Patent No. 1543563 discloses a process for the preparation of clavulanic acid salts via precipitation by lithium carbonate.
In European Patent No. 0026044, the use of the tertiary-butylamine salt of clavulanic acid as an intermediate in the preparation of clavulanic acid and pharmaceutically acceptable salts and esters thereof as well as a process for the preparation of clavulanic acid or a pharmaceutically acceptable salt or ester thereof comprising converting the tertiary-butylamine salt of clavulanic acid into clavulanic acid or a pharmaceutically acceptable salt or ester thereof are described. The tertiary-butylamine salt of clavulanic acid, which can be obtained in high purity, has been disclosed in Belgian Patent No. 862211, but only as a suitable ingredient for pharmaceutical formulations. European Patent No. 0026044 further discloses a process for the purification of clavulanic acid or a pharmaceutically acceptable salt or ester thereof which comprises contacting impure clavulanic acid in an organic solvent with tertiary-butylamine, isolating the tertiary-butylamine salt of clavulanic acid, and converting the thus formed tertiary-butylamine salt into calvulanic acid or a pharmaceutically acceptable salt or ester thereof.
Crystalline potassium clavulanate generally exists in the form of rod-like or needle-like crystals, which are generally relatively large, long crystals, sometimes agglomerated into plate-like crystals, and sometimes randomly aggregated into loosely formed bundles. This form of potassium clavulanate can give rise to processing difficulties in that the material does not always flow readily, is of low bulk density, and can be difficult to sieve. U.S. Pat. No. 5,288,861 describes crystalline potassium clavulanate in the form of crystalline rosettes, each comprising a plurality of needle crystals radiating out from a common nucleation point. Such rosette form of crystalline potassium clavulanate has improved flow characteristics and sieving characteristics as compared with the standard needle form potassium clavulanate, thus resulting in advantageous pharmaceutical processing and formulation. Crystalline potassium clavulanate may also exist in a more open rosette, or starburst, form as described in U.S. Pat. No. 5,288,861.
SUMMARY OF THE INVENTION
This invention relates to an improved process for the preparation of potassium clavulanate of the formula (I):
directly from the tertiary-butylamine salt of clavulanic acid which results in greater overall yield and better final product quality than the prior art processes.
The present invention also relates to a new rosette-like starburst crystalline form of potassium clavulanate.
REFERENCES:
patent: 4454069 (1984-06-01), Cook et al.
patent: 4647659 (1987-03-01), Cook et al.
patent: 5288861 (1994-02-01), Clark et al.
patent: 5441945 (1995-08-01), Yoshikawa
patent: 5726170 (1998-03-01), Callewaer
patent: 5821364 (1998-10-01), Weber
patent: 5859238 (1999-01-01), Copar
patent: 5985625 (1999-11-01), Capuder
patent: 0 277 008 (1988-08-01), None
patent: 1508977 (1978-04-01), None
patent: 1543563 (1979-04-01), None
patent: WO 93/25557 (1993-12-01), None
patent: WO 94/21647 (1994-09-01), None
patent: WO 95/21173 (1995-08-01), None
patent: WO 97/05142 (1997-02-01), None
Eggers, D.F. Jr et al, “Physical Chemistry”, 1964, John Wiley, New York, pp. 519-522.*
Pauling, Linus, “General Chemistry, 2nd Ed.”, 1953, Freeman, San Francisco, p141-142.
Butterly Paul Gerard
Keohane Gilroy John
Kosal Esin Fatma
Kinzig Charles M.
McKenzie Thomas C
Shah Mukund J.
SmithKline Beecham Corporation
Williams Janice E.
LandOfFree
Process for preparing potassium clavulanate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for preparing potassium clavulanate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for preparing potassium clavulanate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2873728